Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 1/2015

01-03-2015

Maintenance chemotherapy in the management of epithelial ovarian cancer

Author: Maurie Markman

Published in: Cancer and Metastasis Reviews | Issue 1/2015

Login to get access

Abstract

The fundamental goal of maintenance therapy of cancer is to extend a clinically meaningful survival endpoint (overall, symptom-free, progression-free) while at the same time not substantially interfering with a patient’s quality of life. Several phase 3 randomized trials in ovarian cancer involving different anti-neoplastics (e.g., paclitaxel, anti-angiogenic agents, olaparib) have revealed an improvement in progression-free survival with generally acceptable side effect profiles, and as a result represent in appropriately selected patients a rational therapeutic strategy.
Literature
1.
Maughan, T. S., James, R. D., Kerr, D. J., et al. (2003). Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomized trial. Lancet, 361, 457–464.CrossRefPubMed
2.
Owonikoko, T. K., Ramalingam, S. S., & Belani, C. P. (2010). Maintenance therapy for advanced non-small cell lung cancer: current status, controversies, and emerging consensus. Clinical Cancer Research, 11, 521–529.
3.
Muss, H. B., Case, L. D., Richards, F., et al. (1991). Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. New England Journal of Medicine, 325, 1342–1348.CrossRefPubMed
4.
Katz, M. E., Schwartz, P. E., Kapp, D. S., et al. (1981). Epithelial carcinoma of the ovary: current strategies. Annals of Internal Medicine, 95, 98–111.CrossRefPubMed
5.
Young, P. C., Chabner, B. A., Hubbard, S. P., et al. (1978). Advanced ovarian adenocarcinoma: a prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. New England Journal of Medicine, 299, 1261–1266.CrossRefPubMed
6.
Greene, M. H., Boice, J. D., Jr., Greer, B. E., et al. (1982). Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized trials. New England Journal of Medicine, 307, 1416–1421.CrossRefPubMed
7.
Travis, L. B., Curtin, R. E., Boice, J. D., Jr., et al. (1996). Second malignant neoplasms among long-term survivors of ovarian cancer. Cancer Research, 56, 1564–1570.PubMed
8.
Lambert, H. E., Rustin, G. J., Gregory, W. M., et al. (1997). A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study. Annals of Oncology, 8, 327–333.CrossRefPubMed
9.
Bertelsen, K., Jakobsen, A., Stroyer, J., et al. (1993). A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). Gynecologic Oncology, 49, 30–36.CrossRefPubMed
10.
Hakes, T. B., Chalas, E., Hoskins, W. J., et al. (1992). Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecologic Oncology, 45, 284–289.CrossRefPubMed
11.
Rowinsky, E. K., & Donohower, R. C. (1995). Paclitaxel (taxol). New England Journal of Medicine, 332, 1004–1014.CrossRefPubMed
12.
McGuire, W. P., Rowinsky, E. K., Rosenshein, N. B., et al. (1989). Taxol: a unique anti-neoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Annals of Internal Medicine, 111, 273–279.CrossRefPubMed
13.
Thigpen, J. T., Blessing, J. A., Ball, H., et al. (1994). Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. Journal of Clinical Oncology, 12, 1748–1753.PubMed
14.
Miller, K. D., Sweeney, C. J., & Sledge, G. W., Jr. (2001). Redefining the target: chemotherapeutics as antiangiogenics. Journal of Clinical Oncology, 19, 796–799.
15.
Markman, H., Hakes, T., Barakat, R., et al. (1996). Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer. Journal of Clinical Oncology, 14, 796–799.PubMed
16.
Rohl, J., Kushner, D., & Markman, M. (2001). Chronic administration of single-agent paclitaxel in gynecologic malignancies. Gynecologic Oncology, 81, 201–205.CrossRefPubMed
17.
Von Gruenigen, V., Karlen, J. R., & Waggoner, S. E. (2003). A case of chronic paclitaxel administration in ovarian cancer. Gynecologic Oncology, 89, 532–535.CrossRef
18.
Markman, M., Liu, P. Y., Wilczynski, S., et al. (2003). Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. Journal of Clinical Oncology, 21, 2460–2465.CrossRefPubMed
19.
Markman, M., Liu, P., Wilcyznski, S., et al. (2009). Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecologic Oncology, 114, 195–198.CrossRefPubMedPubMedCentral
20.
Broglio, K. R., & Berry, D. A. (2009). Detecting an overall survival benefit that is derived from progression-free survival. Journal of the National Cancer Institute, 101, 1642–1649.CrossRefPubMedPubMedCentral
21.
Pecorelli, S., Favalli, G., Gadducci, A., et al. (2009). Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 Protocol 1. Journal of Clinical Oncology, 27, 4642–4648.CrossRefPubMed
22.
Del Placido, S., Scambia, G., Di, V. G., et al. (2004). Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. Journal of Clinical Oncology, 22, 2635–2642.CrossRefPubMed
23.
Pfisterer, J., Weber, B., Reuss, A., et al. (2006). Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a Gynecologic Intergroup trial of the AGO-AOVAR and GINECO. Journal of the National Cancer Institute, 98, 1036–1045.CrossRefPubMed
24.
Bolis, G., Danese, S., Tateo, S., et al. (2006). Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study. International Journal of Gynecological Cancer, 16(suppl 1), 74–78.CrossRefPubMed
25.
Alberts, D. S., Jiang, C., Liu, P. Y., et al. (2004). Long-term follow-up of a phase II trial of oral altretamine for consolidation of complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group. International Journal of Gynecological Cancer, 14, 224–228.CrossRefPubMed
26.
27.
Burger, R. A., Sill, M., Monk, B. J., et al. (2007). Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. Journal of Clinical Oncology, 25, 5165–5171.CrossRefPubMed
28.
Cannistra, S. A., Matulonis, U. A., Person, R. T., et al. (2007). Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. Journal of Clinical Oncology, 25, 5180–5186.CrossRefPubMed
29.
Burger, R. A., Brady, M. F., Bookman, M. A., et al. (2011). Incorporation of bevacizumab in the primary treatment of ovarian cancer. New England Journal of Medicine, 365, 2473–2483.CrossRefPubMed
30.
Perren, T. J., Swart, A. M., Pfisterer, J., et al. (2011). A phase 3 trial of bevacizumab in ovarian cancer. New England Journal of Medicine, 365, 2484–2496.CrossRefPubMed
31.
Aghajanian, C., Blank, S. V., Goff, B. A., et al. (2012). OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. Journal of Clinical Oncology, 30, 2039–2045.CrossRefPubMedPubMedCentral
32.
Pujade-Lauraine, E., Hilpert, F., Weber, B., et al. (2012). AURELIA: a randomized phase III trial evaluating bevacizumab plus chemotherapy for platinum-resistant ovarian cancer. Journal of Clinical Oncology, 30 (suppl; LBA 5002).
33.
Burger, R. A. (2011). Overview of anti-angiogenic agents in development for ovarian cancer. 121:230–238.
34.
De Bois, A., Floquet, A., Kim, J. W., et al. (2013). Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: results of an international Intergroup trial (AGO-OVAR 16). Journal of Clinical Oncology, 31(suppl; LBA 5503).
35.
Hall, G. D., Brown, J. M., Coleman, R. E., et al. (2004). Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire Gynecology Group randomized phase III study. British Journal of Cancer, 91, 621–626.CrossRefPubMedPubMedCentral
36.
Alberts, D. S., Hannigan, E. V., Liu, P. Y., et al. (2006). Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: an intergroup study. Gynecologic Oncology, 100, 133–138.CrossRefPubMed
37.
Berek, J., Taylor, P., McGuire, W., et al. (2009). Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. Journal of Clinical Oncology, 27, 418–425.CrossRefPubMed
38.
Sabbatini, P., Harter, P., Scambia, G., et al. (2013). Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO—The MIMOSA Study. Journal of Clinical Oncology, 31, 1554–1561.CrossRefPubMed
39.
Vergote, I. B., Jimeno, A., Joly, F., et al. (2014). Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first line platinum-based chemotherapy for ovarian carcinoma: a European Organization for Research and Treatment of Cancer—Gynaecological Cancer Group and Gynecologic Cancer Intergroup study. Journal of Clinical Oncology, 32, 320–326.CrossRefPubMed
40.
Schilder, R. J., Sill, M. W., Chen, X., et al. (2005). Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group study. 11:5539–5548.
41.
Fong, P. C., Yap, T. A., Boss, D. S., et al. (2010). Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. Journal of Clinical Oncology, 28, 2512–2519.CrossRefPubMed
42.
Ledermann, J., Harter, P., Gourley, C., et al. (2012). Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New England Journal of Medicine, 366, 1382–1392.CrossRefPubMed
43.
Farmer, H., McCabe, N., Lord, C. J., et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 434, 917–921.CrossRefPubMed
44.
Hennessy, B. T. J., Timms, K., Carey, M. S., et al. (2010). Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from PARP inhibitors in ovarian cancer. Journal of Clinical Oncology, 28, 3570–3576.CrossRefPubMedPubMedCentral
45.
Ledermann, J. A., Harter, P., Gourley, C., et al. (2013). Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation. Journal of Clinical Oncology, 31(suppl; Abstract 5505).
Metadata
Title
Maintenance chemotherapy in the management of epithelial ovarian cancer
Author
Maurie Markman
Publication date
01-03-2015
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 1/2015
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-014-9537-x

Other articles of this Issue 1/2015

Cancer and Metastasis Reviews 1/2015 Go to the issue

Announcement

Biographies

EditorialNotes

Preface

OriginalPaper

Primary debulking surgery and neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian carcinoma

Clinical

Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring

Clinical

Immunotherapy of melanoma: Present options and future promises

Erratum

Erratum to: Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits